NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

NovaBridge BiosciencesNASDAQ: NBP

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development growth accelerates

Q4 FY2025 research & development of $7.96M rose 32.0% year over year, ahead of the -94.8% change in trailing-twelve-month research & development. Sequentially, it rose 150.5% from the prior quarter. Over 3 fiscal years it compounded at -61.3% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.0% holds above the trailing-twelve-month pace of -94.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$7.96M+150.5% QoQ
Last fiscal yearDec 2025
$8.99M-94.3% YoY
LTMSep 2025
$13.28M-94.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year-94.3%——
3-year CAGR-61.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

Mixed currencies · from the income statement

Latest · FY2025
8.99M USD
Year-over-year change
—

Research & Development vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -94.8% is the lowest of 10, against a peer median of +17.5%.
  • Over three fiscal years its annual growth of -61.3% compares with a peer median of +15.9%.
NBP Competitors
Research & Development for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M USD-14.3%-5.0%—
ENGNenGene Holdings Inc.LTM Apr 2026$98.75M USD+56.7%+82.8%—
AURAAura Biosciences, Inc.LTM Mar 2026$94.92M USD+19.3%+28.8%—
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$58.13M USD+16.8%+6.7%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$35.87M USD+29.3%+13.9%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M USD—+131.7%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$26.95M USD+28.1%+46.4%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.28M CNY-94.8%-61.3%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$10.04M USD-71.3%-23.4%—
Peer median (excluding NBP) —+17.5%+15.9%185483.3%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.